Psyence Biomedical Ltd.

Psyence Biomedical Ltd. is a Canada-based life science biotechnology company focused on the development and commercialization of nature-derived psilocybin products for neurological and mental health disorders. The company's mission is to advance a portfolio of evidence-based therapeutics targeting unmet mental health needs, particularly within palliative care and addiction, through a fully integrated biotechnology platform. Its headquarters are located in Toronto, Canada.

The company's primary product candidate is PEX010, a 25mg naturally derived psilocybin formulation currently undergoing a Phase IIb clinical study. This trial evaluates PEX010 for the treatment of adjustment disorder in patients with an incurable cancer diagnosis within a palliative care context. Psyence Biomedical also focuses on ibogaine therapies and aims to be a licensed pharmaceutical-grade supplier of ibogaine, expanding its scope to include longevity science.

Recent notable developments include the initiation of patient dosing in its Phase IIb trial for adjustment disorder and the expansion of its Australian clinical site network. In October 2025, Jody Aufrichtig assumed the role of Chief Executive Officer, succeeding Dr. Neil Maresky, who transitioned to Global Head of Clinical Development. The company has also made strategic follow-on investments in PsyLabs to secure the supply of GMP-grade psilocybin and ibogaine, and regained compliance with Nasdaq listing requirements.